SCHEMBL31469256

SCHEMBL31469256

COc1cc2ncnc(-c3c(-c4ccccc4)cnn3C3CCCCO3)c2cc1NC(=O)C1CC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.44
GAA P10253 2/20 0.44
HTT P42858 2/20 0.40
LMNA P02545 2/20 0.40
USP2 O75604 1/20 0.40
EGFR P00533 6/20 0.39
SMN1; SMN2 Q16637 3/20 0.38
GSK3B P49841 2/20 0.38
MAPT P10636 2/20 0.38
MALT1 Q9UDY8 1/20 0.38
HPGD P15428 1/20 0.38
TSHR P16473 2/20 0.38
AAK1 Q2M2I8 1/20 0.37
ERBB4 Q15303 4/20 0.37
ERBB2 P04626 3/20 0.37
KDR P35968 1/20 0.37
KDM4E B2RXH2 1/20 0.37
NPC1 O15118 1/20 0.37
NFKB1 P19838 1/20 0.37
RAB9A P51151 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31469237 0.87 TSHR (0.40) ALDH1A1GAALMNAUSP2EGFR
SCHEMBL31469378 0.84 ATR (0.47) ALDH1A1GAATSHR
SCHEMBL31469324 0.78 ATR (0.40) SMN1; SMN2NPC1RAB9A
SCHEMBL31469333 0.77 EGFR (0.43) ALDH1A1GAAEGFRMALT1ERBB4
SCHEMBL31469351 0.77 GSK3B (0.46) ALDH1A1GAAEGFRGSK3BERBB4
SCHEMBL26110729 0.77 EGFR (0.48) EGFRERBB4ERBB2
SCHEMBL26113555 0.76 EGFR (0.48) ALDH1A1GAAEGFRMAPTMALT1
SCHEMBL26586326 0.74 EGFR (0.50) ALDH1A1EGFRERBB4ERBB2
SCHEMBL26584629 0.73 HTT (0.51) ALDH1A1GAAHTTLMNAEGFR
SCHEMBL26111167 0.72 EGFR (0.43) ALDH1A1GAAHTTEGFRERBB4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122029158-A EGFR inhibitors 缆图药品公司 2026-05-12 CN disclosed
WO-2025080784-A1 EGFR INHIBITORS BLUEPRINT MEDICINES CORPORATION (US) 2025-04-17 WO disclosed